Ng F, Mastoroudes H, Paul E, Davies N, Tibballs J, Hochhauser D, Mayer A, Begent R, Meyer T
Academic Department of Oncology, Royal Free and University College Medical School, Rowland Hill Street, London, UK.
Clin Oncol (R Coll Radiol). 2007 Sep;19(7):551-6. doi: 10.1016/j.clon.2007.04.003. Epub 2007 May 22.
To compare the complication rates of Hickman lines and Port-a-Caths in patients undergoing infusional chemotherapy for solid tumours.
A single institution retrospective analysis comparing complication rates for 30 Hickman lines and 33 Port-a-Caths inserted for chemotherapy in adults with solid tumours was carried out.
Patients were well matched in terms of primary site and chemotherapy regimen. In both cases, over 85% were inserted radiologically under local anaesthetic. The total time in situ for Hickman lines and Port-a-Caths was 3539 days (median 83, range 6-585) and 5783 days (median 158, range 20-456), respectively. The complication rate for Hickman lines was 5.09/1000 catheter days, almost five times that for Port-a-Caths, with 1.04/1000 catheter days, a relative risk of 4.9 (confidence interval: 1.9-15.1, P=0.0003). Most (73%) complications occurred within 4 weeks of insertion. However, some arose much later: the range of time to complication was 1-304 days for Hickman lines and 1-132 days for Port-a-Caths. Infection was the most common complication, accounting for nine of 18 Hickman line complications and five of six Port-a-Cath complications, giving an overall infection rate of 2.54/1000 catheter days and 0.86/1000 catheter days, respectively. Additionally, Hickman lines had a 26% leakage rate or displacement rate, which did not occur at all in the Port-a-Cath group. Complications required the removal of 16 Hickman lines and five Port-a-Caths. The rate of removal was five times higher for Hickman lines (Hickman lines=4.52/1000 catheter days, Port-a-Caths=0.86/1000 catheter days, P=0.0027). Overall, the cost of Port-a-Caths was less than that of Hickman lines.
In this study, Port-a-Caths were shown to be both safer and cheaper than Hickman lines for patients requiring infusional chemotherapy.
比较希克曼线(Hickman线)和植入式静脉输液港(Port-a-Cath)在实体瘤患者接受灌注化疗时的并发症发生率。
进行了一项单机构回顾性分析,比较了为成年实体瘤患者插入的30条希克曼线和33个植入式静脉输液港的并发症发生率。
患者在原发部位和化疗方案方面匹配良好。在这两种情况下,超过85%是在局部麻醉下通过放射学方法插入的。希克曼线和植入式静脉输液港的总在位时间分别为3539天(中位数83天,范围6 - 585天)和5783天(中位数158天,范围20 - 456天)。希克曼线的并发症发生率为5.09/1000导管日,几乎是植入式静脉输液港的五倍,后者为1.04/1000导管日,相对风险为4.9(置信区间:1.9 - 15.1,P = 0.0003)。大多数(73%)并发症发生在插入后的4周内。然而,有些并发症出现得要晚得多:希克曼线并发症发生时间范围为1 - 304天,植入式静脉输液港为1 - 132天。感染是最常见的并发症,希克曼线的18例并发症中有9例、植入式静脉输液港的6例并发症中有5例是感染,总体感染率分别为2.54/1000导管日和0.86/1000导管日。此外,希克曼线有26%的渗漏率或移位率,而植入式静脉输液港组完全没有这种情况。并发症导致16条希克曼线和5个植入式静脉输液港被移除。希克曼线的移除率高出五倍(希克曼线 = 4.52/1000导管日,植入式静脉输液港 = 0.86/1000导管日,P = 0.0027)。总体而言,植入式静脉输液港的成本低于希克曼线。
在本研究中,对于需要进行灌注化疗的患者,植入式静脉输液港比希克曼线更安全且成本更低。